<DOC>
	<DOCNO>NCT02387216</DOCNO>
	<brief_summary>The purpose study determine whether combination MM-121 plus docetaxel pemetrexed effective docetaxel pemetrexed alone regard OS patient heregulin-positive NSCLC .</brief_summary>
	<brief_title>A Study MM-121 Combination With Chemotherapy Versus Chemotherapy Alone Heregulin Positive NSCLC</brief_title>
	<detailed_description>This study randomize , open-label , international , multi-center , phase 2 study patient Heregulin-positive NSCLC progress follow three systemic therapy locally advance metastatic disease , one must anti-PD-1 anti-PD-L1 therapy . All patient initially screen heregulin status . Eligible patient randomize receive MM-121 combination investigator 's choice either docetaxel pemetrexed versus docetaxel pemetrexed alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Large Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients diagnosis cytologically histologically confirm NSCLC either metastatic disease ( stage IV ) Stage IIIB disease amenable surgery curative intent Failed antiPD1 antiPDL1 therapy receive 3 prior systemic therapy primary recurrent disease Tissue submit HRGbiomarker test ECOG performance status ( PS ) 0 1 Known ALK mutation Presence exon 19 deletion exon 21 ( L858R ) substitution EGFR gene Received &gt; 3 prior systemic anticancer drug regimen locally advance disease Prior treatment antiErbB3 antibody CTCAE grade 3 high peripheral neuropathy Symptomatic CNS metastases CNS metastasis require steroid Any active malignancy require systemic therapy Clinically significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>heregulin</keyword>
	<keyword>ErbB3</keyword>
	<keyword>docetaxel</keyword>
	<keyword>pemetrexed</keyword>
</DOC>